AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02458729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Normal Saline (3 hours after operation)
Description: 0.9% Normal Saline 20ml administered intravenously 3 hours after operation
Study NCT02458729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal Saline (3 hours after operation)
Description: 0.9% Normal Saline 20ml administered intravenously 3 hours after operation
Study NCT02458729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rivaroxaban (10mg)
Description: Oral rivaroxabam (10mg) QD on PostOp Day 1 to 14
Study NCT02458729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rivaroxaban (10mg)
Description: Oral rivaroxabam (10mg) QD on PostOp Day 1 to 14
Study NCT02278003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: memory test
Study NCT02278003 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: memory test
Study NCT02278003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Study NCT06261255 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ATT + EMD
Description: All surgical treatments will be performed by the same experienced periodontist (IP) after the administration of local anesthesia. Initially, tooth sectioning of the hopeless tooth (receptor) will be carried out using fissure carbide burs, and the remaining fragments will be extracted as minimally invasively as possible. A tooth-supported surgical guide will be used to prepare the recipient site following the 3D planning. Additional alveoloplasty procedures will be performed with round diamond burs if necessary to adapt the CARP model to the virtual planning position. The donor tooth will be extracted as atraumatically as possible, utilizing a piezoelectric surgical instrument if osteotomy is required, and avoiding the use of elevators or forceps over the root surface. Extraorally, EMD will be applied to the root surface of the donor tooth
Study NCT02771301 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: dendritic cells
Description: Concurrent of radiotherapy and chemotherapy plus 12 cycles of dendritic cells and cytotoxic lymphocytes treatment
Study NCT02101463 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: surgeon-modified fenestrated-branched stent-grafts (sm-FBSG)
Study NCT02875418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUM
Description: STUDY DESIGN~1. Explanation regarding the study and assessing eligibility criteria.~2. Signing an informed consent.~3. Recording of uterine contractions by both EUM and tocodynamometry. A correlation between EUM and tocodynamometry will be calculated. For the purpose of this study, a positive EUM or tocodynamometry will be defined as 3 at least 3 contractions in 30 minutes.
Study NCT02875418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tocodynamometry
Description: STUDY DESIGN~1. Explanation regarding the study and assessing eligibility criteria.~2. Signing an informed consent.~3. Recording of uterine contractions by both EUM and tocodynamometry. A correlation between EUM and tocodynamometry will be calculated. For the purpose of this study, a positive EUM or tocodynamometry will be defined as 3 at least 3 contractions in 30 minutes.
Study NCT00571714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alpha-2a and ribavirin
Description: Peginterferon alpha-2a 180mcg by subcutaneous injection every week and weight based ribavirin, 800 to 1400mg/day by mouth in two divided doses every day for 48 weeks
Study NCT00571714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alpha-2a , ribavirin and betaine
Description: Peginterferon alpha-2a 180mcg given by subcutaneous injection every week plus weight based ribavirin 800 to 1400 mg/day by mouth in divided doses twice a day plus betaine 10 gm dissolved in juice twice a day for twelve weeks followed by peginterferon alpha-2a 180 mcg given by subcutaneous injection every week plus weight based ribavirin 800 to 1400mg/day by mouth in divided doses twice a day for 36 weeks.
Study NCT03061513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ubiquinol
Description: Ubiquinol caplets 600mg/day
Study NCT03061513 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT00683410 — intervention group
Intervention type: BIOLOGICAL
Intervention: Pneumococcal Conjugate Vaccine, 7-valent (Prevenar)
Study NCT00217672 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Patients receive bevacizumab 15 mg/kg intravenously (I.V.) every 3 weeks until disease progression, unacceptable toxicity, or consent withdrawal.
Study NCT00217672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: docetaxel: 75 mg/m2 IV q3 weeks. Subjects continue on dosing until they experience unacceptable toxicity, disease progression, or withdrawal of patient consent.
Study NCT00217672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: docetaxel: 75 mg/m2 IV q3 weeks. Subjects continue on dosing until they experience unacceptable toxicity, disease progression, or withdrawal of patient consent.
Study NCT00370799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caudal epidural injection
Description: group 1: Caudal epidural injection local anesthetics only
Study NCT00370799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caudal Epidural Injection with generic Celestone
Description: Group 2. Caudal Epidural Injection local anesthetic with 6mg of non-particulate Celestone
Study NCT00370799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caudal Epidural Injection with Celestone
Description: Group 3. Caudal Epidural Injection with local anesthetic with 6 mg of brand name Celestone
Study NCT00370799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caudal Epidural Injection with DepoMedrol
Description: Group 4. local anesthetic with 40 mg of alcohol-free DepoMedrol
Study NCT02982213 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Companion Present
Description: A companion will be present during the epidural catheter placement.
Study NCT01738867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1521498
Description: White HPMC capsule containing 10 mg of GSK1521498
Study NCT01738867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX)
Description: Swedish orange gelatin capsule containing 25mg of NTX or 50mg of NTX
Study NCT01738867 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules to GSK1521498 or NTX
Study NCT03278288 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WellWe-Intervention group
Description: Participants (families) allocated to the intervention group get to use WellWe-app before entering to health visit to assess the current situation of their wellbeing and utilizing these results during the health visit. The access to WellWe-app is permitted throughout the data collection period. Participants (PHNs) randomized to the intervention group get standardized two hour WellWe-training, WellWe-handbook and full access to the WellWe-app during the data collection period.
Study NCT05875155 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Infectious Disease Labwork
Description: Infectious disease labs will be drawn and resulted.
Study NCT05875155 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fertility-Based Labwork
Description: Other labwork to understand fertility may be drawn.
Study NCT02150824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: BI 187004 medium dose matching placebo once daily
Study NCT03211637 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Wounds Protocol
Description: Nurses who have been trained to use wound dressing supplies and also on the use of the protocol.
Study NCT03211637 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Wounds Protocol
Description: Nurses who have been trained to use wound dressing supplies and also on the use of the protocol.
Study NCT01450072 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Selective Venography followed by therapeutic balloon angioplasty
Description: Venography followed by therapeutic balloon angioplasty
Study NCT01450072 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control arm
Description: Venography and sham angioplasty
Study NCT02150824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: BI 187004 high dose matching placebo once daily add on to background metformin
Study NCT02512042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test-Brinzolamide 1% Ophthalmic suspension
Study NCT02512042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference-Brinzolamide 1% Ophthalmic suspension
Study NCT01964261 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neural Prosthetic System 2 (NPS2)
Description: The NPS2 comprises 3 NeuroPort Arrays (SIROF). The tip of the electrodes are sputtered iridium oxide film (SIROF). Each array is comprised of 100 1.5 mm microelectrodes organized on a 4mm x 4mm silicon base that is 0.25 mm thick. Each microelectrode is insulated with Parylene-C polymer and is electrically isolated from neighboring electrodes by non-conducting glass. Of the 100 electrodes, 96 are wire bonded using 25m gold alloy insulated wires sealed with a silicone elastomer. The wire bundle is potted to a printed circuit board with epoxy, the circuit board is inserted into the Patient Pedestal (percutaneous connector), and then the Patient Pedestal is filled with silicone elastomer. Two fine platinum reference wires are also attached to the Patient Pedestal. The Patient Pedestal is 19 mm wide at the skin interface.
Study NCT04073420 — intervention group
Intervention type: DEVICE
Intervention: Surgical Heart Valve Repair Products
Description: Surgical heart valve repair products.
Study NCT04073420 — intervention group
Intervention type: DEVICE
Intervention: Surgical Heart Valve Replacement Products
Description: Surgical heart valve replacement products.
Study NCT03158246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic Zoledronic Acid
Description: Generic Zoledronic Acid (Yigu®) 5mg/100ml injection
Study NCT03158246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Original Zoledronic Acid
Description: Original Zoledronic Acid (Aclasta®) 5mg/100ml injection
Study NCT03158246 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: calcium
Description: 600mg/d calcium for oral daily
Study NCT03158246 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium
Description: 600mg/d calcium for oral daily
Study NCT03158246 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D
Description: 925IU/d vitamin D for oral daily
Study NCT03158246 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: 925IU/d vitamin D for oral daily
Study NCT01644331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: IV furosemide plusTolvaptan (given at 0, 24 and 48 hours)
Study NCT01644331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV furosemide plus oral placebo (given at 0, 24 and 48 hours)
Study NCT02346279 — intervention group
Intervention type: OTHER
Intervention: Questionnaires, EDSS, physical test
Description: 6 Meter timed walking test, Nine Hole Peg Test, Berg balance Scale, MSQPT, HAQUAMS, Transition Questionnaire for Patients, Transition Questionnaire for Therapists, EDSS, 6 Minute Walking Test
Study NCT01161966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: Zonisamide capsules 100 mg
Study NCT01161966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonegran
Description: Zonegran Capsules 100 mg of EISAI INC
Study NCT02221726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-35684-AAA-023: Size 1; small patch
Description: Placebo (matched to Fentanyl transdermal delivery device system \[TDDS\]) JNJ-35685-AAA-G-023 TDDS, 5.5 centimeter square (cm\^2) will be applied vertically to 1 side of the paraspinal region, replicated 3 times, and worn for 72 hours.
Study NCT02221726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-35684-AAA-023: Size 2; large patch
Description: Placebo (matched to Fentanyl transdermal delivery device system \[TDDS\]) JNJ-35685-AAA-G-023 TDDS, 44 cm\^2 (Size 1; small patch) will be applied vertically to other side of the paraspinal region, replicated 3 times, and worn for 72 hours.
Study NCT02779231 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bi-directional texting
Study NCT02354573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: All subjects will receive Ivabradine 7.5mg twice daily for 2 weeks in a double-blind randomized crossover design.
Study NCT02354573 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ivabradine
Description: All subjects will receive Ivabradine 7.5mg twice daily for 2 weeks in a double-blind randomized crossover design.
Study NCT01784484 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT02085980 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser treatment
Description: The laser handpiece (probe) will be deposited in the vaginal canal and the laser energy will be delivered through the handpiece
Study NCT04046744 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary brachial plexus block with a long-acting local anesthetic
Description: axillary block with 15-30 ml Ropivacaine 0,5%.
Study NCT04046744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary brachial plexus block with a short-acting local anesthetic + Analgesic block at the elbow with a long-acting local anesthetic
Description: axillary block with 15-30 ml Lidocaine 1,5% + radial and medial nerve block at the elbow with 3-7 ml Ropivacaine 0,5%.
Study NCT04046744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: axillary block with 15-30 ml Ropivacaine 0,5%
Study NCT04046744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: radial and medial nerve block at the elbow with 3-7 ml Ropivacaine 0,5%
Study NCT04046744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: axillary block with 15-30 ml Lidocaine 1,5%
Study NCT02138500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06372865
Description: Single, oral dose administration of TBD dose PF-06372865 using tablet/extemprep formulation.
Study NCT04847856 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetic care Information, education, and communication intervention will be delivered by relevant and trained health animators working in chronic care clinic.
Description: The training sessions and the IEC materials were adapted from John Hopkins University studies on self-care for diabetic patients.
Study NCT04279405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YY-20394
Description: YY-20394 80mg tablet administered orally once daily
Study NCT00045968 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dendritic cell immunotherapy
Description: Two intradermal (i.d.) injections of DCVax-L(treatment cohort) or autologous PBMC (placebo cohort) per treatment. Treatments will be given at days 0, 10, 20, and at weeks 8, 16, 32, 48, 72, 96 and 120.
Study NCT00045968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dendritic cell immunotherapy
Description: Two intradermal (i.d.) injections of DCVax-L(treatment cohort) or autologous PBMC (placebo cohort) per treatment. Treatments will be given at days 0, 10, 20, and at weeks 8, 16, 32, 48, 72, 96 and 120.
Study NCT03068611 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Web-based Smoking Cessation
Description: A website and text messaging program that is publicly available through BecomeAnEX.com. Participants have access to the website whenever they wish.
Study NCT03068611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol-focused Web-Based Smoking Cessation
Description: A website and text messaging program that is publicly available through BecomeAnEX.com. Participants have access to the website whenever they wish.
Study NCT05038670 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Replacement
Description: Participant will undergo total knee replacement performed via anterior parapatellar approach with either PERSONA PS or JOURNEY II BCS
Study NCT03562910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HelpSteps application
Description: Mobile or tablet-based tool that screens for social needs and refers to local agency based on needs and proximity.
Study NCT03031132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HP-Beverage Breakfast
Description: Participants will consume high protein beverage (shake) breakfast meals each morning.
Study NCT03031132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HP-Solid Breakfast
Description: Participants will consume high protein solid (traditional food items) breakfast meals each morning.
Study NCT03031132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breakfast Skipping
Description: Participants will skip breakfast each morning.
Study NCT01851460 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cool-tip RF Ablation System
Description: RFA therapy will be administered according to the instructions of the RFA device manufacturer. After infiltration of the skin (for percutaneous approach) with a local anesthetic, the needle probe will be directed into the lesion. For all methods, the needle placement is confirmed to be within the lesion by ultrasound or other imaging modality as appropriate. After confirming needle placement, the lesion will be heated to a target temperature of >75 (Infinite)c for up to 15 minutes. The exposure time may be varied depending on the temperatures achieved. Depending on the size of the lesion to be ablated, multiple passes of the probe as well as multiple ablation cycles may be performed. Adequacy of ablation will be monitored by ultrasound throughout the procedure. Depending on the size of the lesions and the time required to complete the ablation, multiple lesions may be treated as staged procedures so as to improve safety.
Study NCT03240354 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saline cuff
Description: Cuff of endotracheal tube inflated with saline rather than air (control)
Study NCT03240354 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Cuff of endotracheal tube inflated with air
Study NCT02105883 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use of identification badge during scenarios
Study NCT01694264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Entecavir (Baraclude (Bristol-Myers Squibb) 0.5mg.) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
Study NCT01694264 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of Entecavir (prepared by Bristol-Myers Squibb) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
Study NCT04650022 — intervention group
Intervention type: DEVICE
Intervention: Mechanical thrombectomy
Description: Stent retriever for treatment of cerebral arterial occlusions
Study NCT02150824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 187004
Description: BI 187004 high dose once daily add on to background metformin
Study NCT01655056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral
Study NCT00619736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSA-789
Study NCT02150824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: BI 187004 low dose matching placebo once daily
Study NCT02150824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 187004
Description: BI 187004 medium dose once daily
Study NCT02150824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 187004
Description: BI 187004 low dose once daily
Study NCT01655056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral
Study NCT03236883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Chemotherapy: Gemcitabine is administered Intravenous injection once a week，at a dose of 1000 mg/m2, for 3consecutive weeks,followed by a 7-days rest,repeated every 4weeks,three times in all.
Study NCT03236883 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: Chemotherapy: Gemcitabine is administered Intravenous injection once a week，at a dose of 1000 mg/m2, for 3consecutive weeks,followed by a 7-days rest,repeated every 4weeks,three times in all.
Study NCT03236883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GPBSC
Description: immunotherapy :GPBSC were collected from donor .Cells were infused to the patients in 4 week,at a dose of (2-3)\*10\^8/kg,once a month,repeated every 4weeks,three times in all.